The British National Formulary is divided into various sections; with the main sections on drugs and preparations being organised by body system. Specialist drug” monographs within BNF Publications: identification and reduced level of detail, see How to use BNF Publications online.

Many individuals and organisations contribute towards the preparation of the BNF. It is authored by Pharmaceutical Press, the Royal Pharmaceutical Society's (RPS) knowledge business; and is jointly published by the BMJ (owned by the BMA), and Pharmaceutical Press (owned by the RPS). It is published under the authority of a Joint Formulary Committee (JFC), [2] which comprises pharmacy, medical, nursing, and lay representatives; there are also representatives from the Medicines and Healthcare products Regulatory Agency (MHRA), the UK Health Departments, and a national guideline producer. Genital system infections, antibacterial therapy: addition of an overview section, and updated guidance for the management of syphilis. Tranexamic acid: new indications for haemorrhage following major trauma, and prevention and treatment of haemorrhage following head injury. Council awards honorary membership to past chairman of the Joint Formulary Committee". The Pharmaceutical Journal. 283: 429. 2009 . Retrieved 20 January 2021. Rabies vaccine [update to pre-exposure immunisation booster dose in patients who may have frequent, unrecognised exposures e.g. bat handlers].NICE apps for smartphones and tablets". www.nice.org.uk. National Institute for Health and Care Excellence. April 2014. Archived from the original on 13 August 2014 . Retrieved 19 July 2014.

Adrenaline/epinephrine: recall of Emerade® 500 micrograms and Emerade® 300 micrograms auto-injectors, due to the potential for device failure [National Patient Safety Alert advice]. This update contains 4 significant changes, 1 dose change, 1 new preparation, 1 deleted monograph and 2 deleted preparations. The BNF for Children developed from the British National Formulary (BNF), which prior to 2005 had provided information on the treatment of children, with the doses largely determined by calculations based on the body weight of the child. Non-steroidal anti-inflammatory drugs: potential risks following prolonged use after 20 weeks of pregnancy [MHRA/CHM advice]. Azithromycin [update to dosing for uncomplicated non-gonococcal urethritis in children aged 12 to 17 years old].Drugs that cause hepatotoxicity, drugs with CNS depressant effects, and drugs that increase serum potassium: pharmacodynamic effects drug groups revalidated and updated; see Appendix 1 interactions. Cefotaxime [update to dosing for uncomplicated gonorrhoea, and update to include dosing in children from 12 years old for disseminated gonococcal infection].